Medindia

X

Reportlinker Adds Macular Degeneration - Drug Pipeline Analysis and Market Forecasts to 2016

Friday, April 2, 2010 Research News J E 4
Advertisement


NEW YORK, April 1 Reportlinker.com announces that a new market research report is available in its catalogue:

Macular Degeneration - Drug Pipeline Analysis and Market Forecasts to 2016

http://www.reportlinker.com/p0185946/Macular-Degeneration---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html

Macular Degeneration - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist's new report, "Macular Degeneration - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global macular degeneration market. The report identifies the key trends shaping and driving the global macular degeneration market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global macular degeneration sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope

The report analyzes market opportunities and challenges for the global macular degeneration market. Its Scope includes

- Annualized global macular degeneration market revenues data from 2001 to 2009, forecast forward for seven years to 2016.

- Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

- Pipeline analysis data provides a split across different phases, mechanism of actions being developed and emerging trends. Key classes of mechanism of action include as VEGF targetors, angiogenesis inhibitors, photosensitizers, antioxidants, C5 inhibitors, choroidal neovascularization inhibitors, multi-kinase angiogenesis inhibitors, tyrosine kinase inhibitors, FKBP12 binders, mTOR inhibitors, and visual cycle inhibitors.

- Analysis of the current and future market competition in the global macular degeneration market. Key market players covered are Alcon Inc., Miravant Pharmaceuticals, Novartis AG, BioInvent International AB, MacuSight, Inc., Ophthotech Corporation, Acucela Inc., Alexion Pharmaceuticals Inc., Inotek Pharmaceuticals, Inc., Jerini AG, Neurotech Usa, Inc., Oxford BioMedica, sanofi-Aventis, Paloma Pharmaceuticals, Inc., Pfizer Inc., PhiloGene Inc., pSivida Corporation, Resolvyx Pharmaceuticals, Inc., Targa Therapeutics Corp., and Tracon Pharma Inc.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with macular degeneration.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global macular degeneration market.

- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global macular degeneration market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global macular degeneration market landscape? - Identify, understand and capitalize.

1 Table of contents

1 Table of contents 3

1.1 List of Tables 5

1.2 List of Figures 5

2 Macular Degeneration Market: Market Characterization 6

2.1 Overview 6

2.2 Macular Degeneration Market Size 6

2.3 Macular Degeneration Market Forecast and CAGR 7

2.4 Drivers and Barriers for the Macular Degeneration Market 8

2.4.1 Drivers for the Macular Degeneration Market 8

2.4.2 Barriers for the Macular Degeneration Market 8

2.5 Opportunity and Unmet Need 8

2.6 Key Takeaway 10

3 Macular Degeneration Market: Competitive Assessment 11

3.1 Overview 11

3.2 Strategic Competitor Assessment 11

3.3 Product Profile for the Major Marketed Products in the Macular Degeneration Market 12

3.3.1 Lucentis 12

3.3.2 Visudyne 13

3.3.3 Macugen 14

3.4 Key Takeaway 16

4 Macular Degeneration Market: Pipeline Assessment 17

4.1 Overview 17

4.2 Strategic Pipeline Assessment 17

4.2.1 Technology Trends Analytical Framework 17

4.3 Macular Degeneration Therapeutics - Promising Drugs under Clinical Development 18

4.4 Molecule Profile for Promising Drugs under Clinical Development 19

4.4.1 Retaane 19

4.4.2 Photrex (SnET2) 19

4.4.3 Zinthionein 20

4.5 Macular Degeneration Therapeutic Market - Clinical Pipeline by Mechanism of Action 21

4.6 Macular Degeneration Pipeline - Pipeline by Clinical Phases of Development 22

4.6.1 Macular Degeneration Therapeutics - NDA Filed 22

4.6.2 Macular Degeneration Therapeutics - Phase III Clinical Pipeline 22

4.6.3 Macular Degeneration Therapeutics - Phase II Clinical Pipeline 23

4.6.4 Macular Degeneration Therapeutics - Phase I Clinical Pipeline 24

4.6.5 Macular Degeneration Therapeutics - Preclinical Pipeline 25

4.6.6 Macular Degeneration Therapeutics - Discovery Pipeline 26

4.7 Discontinued/ Suspended Drugs for Macular Degeneration 26

4.8 Key Takeaway 27

5 Global Macular Degeneration Market: Implications for Future Market Competition 28

6 Macular Degeneration Market: Future Players in the Macular Degeneration Disease Market 30

6.1 Introduction 30

6.2 Alcon Inc. 31

6.2.1 Company Overview 31

6.2.2 Business Description 32

6.2.3 Company Macular Degeneration Pipeline 33

6.2.4 Retaane 33

6.3 Novartis AG 34

6.3.1 Company Overview 34

6.3.2 Business Description 34

6.3.3 Company Macular Degeneration Pipeline 35

6.4 BioInvent International 35

6.4.1 Company Overview 35

6.4.2 Business Description 35

6.4.3 Company Macular Degeneration Pipeline 36

6.5 MacuSight, Inc. 36

6.5.1 Company Overview 36

6.5.2 Company Pipeline 36

6.6 Ophthotech Corporation 36

6.6.1 Company Overview 36

6.6.2 Company Macular Degeneration Pipeline 37

6.7 Pfizer AG 37

6.7.1 Company Overview 37

6.7.2 Business Description 37

6.7.3 Company Macular Degeneration Pipeline 38

6.8 Acucela Inc. 38

6.8.1 Company Overview 38

6.8.2 Company Pipeline 38

6.9 Alexion Pharmaceuticals 38

6.9.1 Company Overview 38

6.9.2 Business Description 39

6.9.3 Company Pipeline 39

6.10 Sanofi-Aventis 39

6.10.1 Company Overview 39

6.10.2 Business Description 40

6.10.3 Company Pipeline 40

6.11 pSivida Corporation 40

6.11.1 Company Overview 40

6.11.2 Business Description 41

6.11.3 Company Pipeline 41

7 Macular Degeneration Market: Appendix 42

7.1 Market Definitions 42

7.2 Abbreviations 42

7.3 Research Methodology 43

7.3.1 Coverage 44

7.3.2 Secondary Research 44

7.3.3 Forecasting 44

7.3.4 Primary Research 47

7.3.5 Expert Panels 47

7.4 Contact Us 47

7.5 Disclaimer 47

7.6 Sources 48

1.1 List of Tables

Table 1: Macular Degeneration Market, Global, Revenues ($m), 2001-2009 7

Table 2: Macular Degeneration Market, Global, Revenues ($m), 2009-2016 7

Table 3: Major Marketed Products Comparison in Macular Degeneration Market, 2010 15

Table 4: Macular Degeneration Therapeutics - Most Promising Drugs Under Clinical Development, 2010 18

Table 5: Macular Degeneration Therapeutics - NDA Filed, 2010 22

Table 6: Macular Degeneration Therapeutics - Phase III Clinical Pipeline, 2010 22

Table 7: Macular Degeneration Therapeutics - Phase II Clinical Pipeline, 2010 23

Table 8: Macular Degeneration Therapeutics - Phase I Clinical Pipeline, 2010 24

Table 9: Macular Degeneration Therapeutics - Preclinical Pipeline, 2010 25

Table 10: Macular Degeneration Therapeutics - Discovery Pipeline 26

Table 11: List of Discontinued/Suspended Drugs for Macular Degeneration, 2010 26

Table 12: Alcon Inc. - Macular Degeneration Pipeline, 2010 33

Table 13: Novartis AG - Macular Degeneration Pipeline, 2010 35

Table 14: BioInvent International - Macular Degeneration Pipeline, 2010 36

Table 15: MacuSight. - Macular Degeneration Pipeline, 2010 36

Table 16: Ophthotech Corporation - Macular Degeneration Pipeline, 2010 37

Table 17: Pfizer AG - Macular Degeneration Pipeline, 2010 38

Table 18: Acucela Inc. - Macular Degeneration Pipeline, 2010 38

Table 19: Alexion Pharmaceuticals Inc. - Macular Degeneration Pipeline, 2010 39

Table 20: Sanofi-Aventis - Macular Degeneration Pipeline, 2010 40

Table 21: Psivida Corporation - Macular Degeneration Pipeline, 2010 41

1.2 List of Figures

Figure 1: Global Macular Degeneration Market Revenues and Forecast ($m), 2001-2016 7

Figure 2: Opportunity and Unmet Need in the Macular Degeneration Market, 2010 9

Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Macular Degeneration Therapeutics, 2010 12

Figure 4: Technology Trends Analytic Framework - Macular Degeneration Market, 2010 17

Figure 5: Technology Trends Analytic Framework of the Macular Degeneration Pipeline - Description, 2010 18

Figure 6: Macular Degeneration Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2010 21

Figure 7: Macular Degeneration Pipeline by Phase of Clinical Development, 2010 22

Figure 8: Implications for Future Market Competition in Macular Degeneration, 2010 28

Figure 9: Macular Degeneration Therapeutics Market - Clinical Pipeline by Company, 2010 30

Figure 10: Macular Degeneration, Global, Companies That Have the Highest Number of Molecules in the Pipeline, 2010 31

Figure 11: GlobalData Methodology 43

Figure 12: GlobalData Market Forecasting Model 46

Companies mentioned

Alcon Inc.

Novartis AG

BioInvent International

MacuSight, Inc.

Ophthotech Corporation

Pfizer AG

Acucela Inc.

Alexion Pharmaceuticals

Sanofi-Aventis

pSivida Corporation

To order this report:

Pharmaceutical Industry: Macular Degeneration - Drug Pipeline Analysis and Market Forecasts to 2016

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds The Future of Ophthalmic Devices...
S
Reportlinker Adds Point of Care Testing: Evaluatin...